M.B.A

EQS-News: Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Retrieved on: 
Wednesday, April 10, 2024
Research, Conference, Biotechnology, M.B.A, Nikko Hotels, Multiple sclerosis, PST, RSVP

NEW YORK, April 4, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April:

Key Points: 
  • NEW YORK, April 4, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April:
    April 9: Immunic’s MS R&D Day.
  • The MS R&D Day will take place on Tuesday, April 9, 2024, from 10:30 am to 12:30 pm PST in-person at the Hotel Nikko in San Francisco.
  • Dr. Vitt will participate in a fireside chat and one-on-one investor meetings at this virtual conference.
  • A webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

Retrieved on: 
Tuesday, April 9, 2024
College, Neurology, Neoplasm, Brain, M.B.A, Utrecht University, Oncology, Neuro, Central nervous system, Novartis, CNS, GBM, Biostatistics, Committee, Biology, Breast, University, Neurosurgery, PSTV, Cancer, Plus, Science park, Doctor of Philosophy, Glioblastoma, Therapy, Texas A&M University, Drug development, Halozyme, Plus Therapeutics, Pharmaceutical industry

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) has formally joined the Company in a part-time capacity. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.

Key Points: 
  • Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory.
  • In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.
  • Dr. Brenner’s academic work focuses on both clinical cancer management and the development of novel therapies to treat breast and central nervous system tumors.
  • Dr. Brenner has received numerous grants and investigational new drug approvals based on his translational research.

Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, MSD, Ovarian cancer, Mirati Therapeutics, London Business School, University of Coimbra, GSK, BMS, Doctor of Philosophy, Therapy, Algeta, Colorectal cancer, International, Pharmacy, Radiopharmaceutical, Radium-223, Agios Pharmaceuticals, Amgen, Cubist Pharmaceuticals, Takeda Pharmaceutical Company, Bristol Myers Squibb, University, Private sector, The central science, Drug development, Sanofi, Psychiatry, BASF, Master of Science, M.B.A, Science, GE HealthCare, Pharmaceutical industry

“We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.

Key Points: 
  • “We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.
  • “We are also pleased to announce the formation of a Scientific and Clinical Advisory Board, consisting of our highly distinguished founders who are uniquely positioned to support Oncoinvent in our clinical programs.
  • Dr. O’Bryan-Tear has been an adviser to several US and European biotech companies and has held board positions at Fusion Pharmaceuticals and Clarity Pharmaceuticals.
  • In addition, Oncoinvent founding scientists Roy Larsen, Ph.D., and Øyvind Bruland, M.D., Ph.D., previously board members, will lead a newly established Scientific and Clinical Advisory Board.

Jean-Jacques Bienaimé Appointed Chairman of the Board at Owkin

Retrieved on: 
Monday, March 25, 2024
Research, Technology, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Growth, Information technology, BioMarin Pharmaceutical, Intelligence, École, University, M.B.A, Biotechnology Innovation Organization, MD, Medicine, Commerce, Enzyme replacement therapy, Multimedia, Economics

Owkin , a TechBio that combines the best of human and artificial intelligence to find the right treatment for every patient, is very pleased to announce the appointment of Jean-Jacques Bienaimé as Chairman to its Board of Directors.

Key Points: 
  • Owkin , a TechBio that combines the best of human and artificial intelligence to find the right treatment for every patient, is very pleased to announce the appointment of Jean-Jacques Bienaimé as Chairman to its Board of Directors.
  • “We are thrilled to have Jean Jacques Bienaimé join our Board of Directors as the new Chairman,” said Thomas Clozel, MD, co-founder and CEO of Owkin.
  • Mr. Bienaimé studied economics at the Ecole de Commerce de Paris and received an M.B.A from the University of Pennsylvania.
  • Mr. Bienaimé is joining a board of directors led by experienced figures from the biopharmaceutical industry and leading venture capital funds.

Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

Retrieved on: 
Thursday, April 4, 2024
PCR, Growth, New product development, Brigham Young University, Utah Valley University, COVID-19, M.B.A, Sale, University, Engineering, Laboratory, CCO, BioMérieux, Marketing, FDA, Management

Mr. Abbott holds a Master of Science degree from Brigham Young University and an M.B.A from the Wharton Business School.

Key Points: 
  • Mr. Abbott holds a Master of Science degree from Brigham Young University and an M.B.A from the Wharton Business School.
  • In his new role, Mr. Abbott will play a key role in the development and commercialization of the Co-Dx PCR platform and associated tests.
  • We welcome them in their new roles as the world continues its shift towards a more decentralized approach to diagnostics.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Retrieved on: 
Thursday, April 4, 2024
Research, PST, Multiple sclerosis, Nikko Hotels, Conference, M.B.A, RSVP

NEW YORK, April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April:

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April:
    April 9: Immunic's MS R&D Day.
  • The MS R&D Day will take place on Tuesday, April 9, 2024, from 10:30 am to 12:30 pm PST in-person at the Hotel Nikko in San Francisco.
  • Dr. Vitt will participate in a fireside chat and one-on-one investor meetings at this virtual conference.
  • A webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Mohegan To Appoint Ari Glazer as Chief Financial Officer

Retrieved on: 
Monday, March 11, 2024
Citigroup, Growth, Partnership, Accounting, Columbia Business School, Hospitality, M.B.A, Columbia University, Treasury, Management

UNCASVILLE, Conn., March 11, 2024 /PRNewswire/ -- Mohegan, a global leader in premium entertainment and gaming resorts, has announced that Ari Glazer will be appointed Chief Financial Officer. With over 20 years of investment banking experience advising global gaming and hospitality companies, Mr. Glazer brings a wealth of financial acumen and industry knowledge to the role. He will have responsibility for all finance activities including financial planning and analysis, capital markets, accounting, tax, treasury, procurement and cash management. Mr. Glazer will report to Ray Pineault, President and Chief Executive Officer of Mohegan. 

Key Points: 
  • UNCASVILLE, Conn., March 11, 2024 /PRNewswire/ -- Mohegan , a global leader in premium entertainment and gaming resorts, has announced that Ari Glazer will be appointed Chief Financial Officer.
  • Mr. Glazer will report to Ray Pineault, President and Chief Executive Officer of Mohegan.
  • "Ari embodies the visionary leadership and deep financial insight that Mohegan is looking for at this stage of our growth," said Ray Pineault.
  • "I look forward to leveraging my experience to enhance our financial performance, optimize our capital structure and support Mohegan's ambitious vision as its new Chief Financial Officer."

Roger Werner Appointed to Clarus’ Board of Directors

Retrieved on: 
Friday, March 8, 2024
The, Discovery, Inc., Motor Trend Group, OLN, Adventure, CLAR, NBC Sports, Sport, University, Speed (TV network), NBC, Fox Sports 1, M.B.A, ESPN, Bally Sports West, Trinity College, Management

SALT LAKE CITY, March 08, 2024 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, announced that the Company’s Board of Directors (the “Board”) appointed Mr. Roger Werner to serve on the Board, effective as of March 8, 2024.

Key Points: 
  • SALT LAKE CITY, March 08, 2024 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, announced that the Company’s Board of Directors (the “Board”) appointed Mr. Roger Werner to serve on the Board, effective as of March 8, 2024.
  • With Mr. Werner’s appointment, the Board will be comprised of 6 directors, five of whom are independent.
  • Mr. Werner has over 40 years of executive leadership experience, which includes building some of television’s most successful sports networks.
  • I look forward to collaborating with the Board and management team to help the Company’s long-term vision come to fruition and create enduring shareholder value.”

John T. Finnell, M.D., M.Sc., and Melissa A. Platt, M.D., Elected to the ABEM Board of Directors

Retrieved on: 
Thursday, February 22, 2024
School, Woman, Multimedia, Graduate medical education, Emergency medicine, Physician, M.B.A, Female, Volunteering, Health administration, Dean (education), ABEM, EPIC, Fellow, Nursing

EAST LANSING, Mich., Feb. 22, 2024 /PRNewswire/ -- The Board of Directors of the American Board of Emergency Medicine (ABEM) has elected two new physician members: John T. Finnell, M.D., M.Sc., and Melissa A. Platt, M.D.

Key Points: 
  • EAST LANSING, Mich., Feb. 22, 2024 /PRNewswire/ -- The Board of Directors of the American Board of Emergency Medicine (ABEM) has elected two new physician members: John T. Finnell, M.D., M.Sc., and Melissa A. Platt, M.D.
  • They are both ABEM-certified physicians and have served as dedicated and valued volunteers for ABEM activities.
  • Dr. Finnell also spearheaded the creation of the School's first ACGME-accredited Clinical Informatics Fellowship, for which he served as Fellowship Director.
  • His many activities as an ABEM volunteer include being an oral examiner (since 2002) and an exam question writer (since 2016).

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Retrieved on: 
Tuesday, February 13, 2024
EMA, Research, Congenital hyperinsulinism, Glomus tumor, Investment, FDA, Report, Diabetic retinopathy, Microsoft Access, Safety, Health care, Hypoglycemia, European Medicines Agency, Pharmacokinetics, Patient, MHRA, M.B.A, Hyperinsulinism, EAP, DME, Pharmaceutical industry

REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the second quarter of fiscal 2024 ended December 31, 2023, and provided an update on recent business developments and outlook.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the second quarter of fiscal 2024 ended December 31, 2023, and provided an update on recent business developments and outlook.
  • Rezolute initiated sunRIZE, a global, pivotal, Phase 3 clinical study in participants with cHI, in Europe and other geographies outside of the U.S.
  • Innovation and Licensing Application Passport (ILAP) designation awarded to RZ358 for the treatment of cHI by the U.K.
  • Topline results expected in the second quarter of 2024.